Xcout IntelWerewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Subscribe to see Werewolf Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Werewolf Therapeutics, Inc. at a glance
Werewolf Therapeutics, Inc. is a biotech company headquartered in Watertown, United States, founded in 2017. It is publicly listed (HOWL) with a market capitalisation of $44.7M. Xcout tracks 12 named people at Werewolf Therapeutics, Inc., including Luke Evnin (Chairman of the Board of Directors).
Werewolf Therapeutics, Inc. leadership
- Luke EvninChairman of the Board of Directors
- Daniel J. HicklinFounder, CEO, President & Director
- Dan HicklinPresident, Chief Executive Officer, and Board member
- Charles CraikScientific Advisory Board Member
- Dario A. VignaliScientific Advisory Board Member
- K. Dane WittrupScientific Advisory Board Member
6 more named people on record for Werewolf Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Werewolf Therapeutics, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $72.1M | 3 named | |
| Series A | $56M | 7 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Werewolf Therapeutics, Inc. news
- AcquisitionM&A registration (S-4)
- AcquisitionWerewolf Therapeutics (HOWL) dispara 120% após fusão com Ambros e aporte de US$ 150 milhões - ADVFN
3 corporate events on record, with sources — see the full timeline →
Investors
Werewolf Therapeutics, Inc. competitors
A few of Werewolf Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Nektar Therapeutics is a biopharmaceutical firm dedicated to identifying and advancing medical treatments for critical health conditions lacking effective therapies, serving markets across the United States and globally. Its diverse pipeline features several promising candidates: Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma. This same compound is also being investigated in Phase 2 trials for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer, in Phase 1/2A for squamous cell carcinoma of the head and neck, in Phase 1/2 for various solid tumors, and in Phase 1B for COVID-19. Another asset, NKTR-358, a cytokine Treg stimulant, is progressing through Phase 2 clinical trials for systemic lupus erythematosus and ulcerative colitis, alongside Phase 1B studies for atopic dermatitis and psoriasis. Furthermore, NKTR-255, an IL-15 receptor agonist, is undergoing Phase 1/2 clinical trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. The company's portfolio also includes NKTR-262, a toll-like receptor agonist in Phase 1/2 trials for solid tumors, among other developmental drug candidates. Nektar has established significant collaborative agreements with a wide array of pharmaceutical companies, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Founded in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Violet Therapeutics, Inc. is a therapeutics company headquartered in Cambridge, Massachusetts, utilizing novel proprietary platforms for drug development.
Mythic Therapeutics, Inc. is a biotechnology research company headquartered in Waltham, Massachusetts. The company is dedicated to developing a proprietary platform to enhance the effectiveness of antibody-drug conjugates and other antibody-based therapeutics.
IpiNovyx Bio, Inc. is a biopharmaceutical company that discovers and develops targeted proteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Utilizing a proprietary technology platform, the company focuses on advancing selective and reversible immunoproteasome inhibitors to create safer and more effective therapies for patients.
76Bio, Inc. is a biotechnology company founded in 2020 and based in Boston, United States. The company develops therapeutics for patients with life-threatening diseases by pioneering targeted protein degraders.
Get Werewolf Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Werewolf Therapeutics, Inc. in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 2 funding rounds before the IPO with the investors in each, and who they co-invest with
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access